Close Menu

ALK Biomarkers

News and reporting on ALK biomarkers.

A group of researchers from Germany's Robert Bosch Hospital and other associated institutions have described a PCR-based method they have developed to detect ALK fusions that takes advantage of some aspects of a method published earlier this year by Pfizer researchers, but which they say could be

A Pfizer research group, working with Seoul's Samsung Medical Center, has published a study demonstrating a multiplex method for detecting ALK, ROS1, and RET fusions in a single assay.

Originally published Oct. 29.

Originally published May 7.

In the first quarter of this year, pharmacogenetically targeted cancer drugs Xalkori and Zelboraf had marked increases in revenues from the previous year's quarter.

Originally published April 9.

Boehringer Ingelheim has launched a campaign to educate healthcare providers about biomarker testing to personalize treatment for non-small cell lung cancer patients.

Insight Genetics has been awarded a contract from the National Cancer Institute worth nearly $1.5 million to begin clinical testing of its qPCR-based assay for ALK mutations in lung cancer.

This article has been updated to correct the name of the Phase I extension trial to Study 1001. Originally published June 3.

Pages

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.